The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase IB/II trial of durvalumab plus doxorubicin combination in patients with advanced soft-tissue sarcoma.
 
Hee Jin Cho
No Relationships to Disclose
 
Nam Suk Sim
No Relationships to Disclose
 
Su-Jin Shin
No Relationships to Disclose
 
Kum-Hee Yun
No Relationships to Disclose
 
Young Han Lee
No Relationships to Disclose
 
Hyun Jung Jun
No Relationships to Disclose
 
Sun Young Rha
Consulting or Advisory Role - Aadi; Amgen; Astellas Pharma; AstraZeneca; Daiichi Sankyo; Eisai; Eutilex; indivumed; LG Chem; MSD Oncology; Ono Pharmaceutical; Toray Industries
Speakers' Bureau - Amgen; AstraZeneca; BMS/Ono; Daiichi Sankyo/UCB Japan; Eisai; MSD Oncology
Research Funding - Amgen (Inst); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daichii Sankyo; Eisai; Indivumed; Lilly; MSD Oncology; Roche/Genentech; Sillajen; Zymeworks
 
Hyo Song Kim
No Relationships to Disclose